An oral interleukin-23 receptor antagonist alleviated the course of psoriasis
A phase II clinical trial of JNJ-77242113, an interleukin-23 receptor antagonist, showed that taking this drug reduced the area of psoriasis lesions and the extent of its symptoms
22.02.2024